[Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Addendum to Commission A22-81]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004355
Original Title: Trastuzumab-Deruxtecan (Mammakarzinom, nach ≥ 2 Vortherapien) Addendum zum Projekt A22-81 (Dossierbewertung)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Breast Neoplasms
  • Trastuzumab
  • Antineoplastic Combined Chemotherapy Protocols
  • Receptor, ErbB-2
  • Immunoconjugates
  • Trastuzumab
  • Breast Neoplasms
  • Benefit Assessment
  • NCT03523585
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.